mCAR27

mCAR27 is a murine ligand-based chimeric antigen receptor (CAR) T-cell therapy designed to target the CD70 antigen, which is frequently overexpressed in glioblastoma and its immunosuppressive microenvironment. Unlike traditional CAR-T cells that utilize a single-chain variable fragment (scFv) for antigen recognition, mCAR27 employs the extracellular domain of the natural CD70 ligand, CD27, to bind its target. This ligand-based approach is intended to mimic natural receptor-ligand interactions, potentially enhancing binding affinity and reducing the risk of immunogenicity associated with non-native scFv sequences. In preclinical studies, mCAR27 has demonstrated potent cytotoxic activity against CD70-expressing murine glioblastoma cells and has shown efficacy in eliminating tumors in orthotopic murine models, suggesting its potential as a therapeutic strategy for high-grade gliomas.

Other names

mCD27z CAR-TmCD-27z CAR-TmCD 27z CAR-Tmurine CD27-based CAR-TmCD70-targeting CAR-TmCD-70-targeting CAR-TmCD 70-targeting CAR-T